[1]
“Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 1, no. 3.1, p. s4, Oct. 2017, doi: 10.25251/skin.1.supp.3.